Ecnoglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. This page compares Ecnoglutide with other GLP-1 receptor agonists, including semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda, Victoza).
Ecnoglutide Alternatives: How It Compares to Other GLP-1 Agonists
Hipa.ai Research · Source: ClinicalTrials.gov / AACT · Last updated: AI-augmented data · 6/7 curated
Source: ClinicalTrials.gov via AACT · Hipa.ai, 2026-05-07Download chart as PNG
The competitive landscape features established treatments such as Liraglutide (Saxenda, Victoza), approved in 2010, and Semaglutide (Wegovy), approved in 2017. While Ecnoglutide has not yet received approval, pipeline drugs Orforglipron, Retatrutide, and Survodutide are currently in Phase 3, potentially 1-2 years behind the latest approvals.
Quick comparison table
| Drug | Class | Approved indications | Dosing | Year approved | Lead pivotal endpoint | Annual cost (rough) |
|---|---|---|---|---|---|---|
| Ecnoglutide | GLP-1 receptor agonist | — | Investigational | Pipeline | — | — |
| Liraglutide (Saxenda, Victoza) | GLP-1 receptor agonist | type 2 diabetes, obesity, cardiovascular risk reduction | 3.0 mg once daily | 2014 | -7.46% @ 56 weeks | $16k |
| Semaglutide (Wegovy) | GLP-1 receptor agonist | chronic weight management, type-2 diabetes (Ozempic), cardiovascular risk reduction | 2.4 mg SC weekly (escalation from 0.25 mg over 16 weeks) | 2021 | -14.9% @ week 68 | $16k |
| Tirzepatide (Zepbound) | GIP/GLP-1 dual receptor agonist | chronic weight management, type-2 diabetes (Mounjaro), obstructive sleep apnea | 5–15 mg SC weekly (titration) | 2023 | -22.5% @ week 72 | $14k |
| Orforglipron | Oral non-peptide GLP-1 receptor agonist | — | Investigational; oral once-daily | Pipeline | — | — |
| Retatrutide | GLP-1/GIP/glucagon triple agonist | — | Investigational | Pipeline | — | — |
| Survodutide | GLP-1/glucagon dual agonist | — | Investigational | Pipeline | — | — |
Cost estimates are list-price approximations and do not reflect rebates, formulary tier, or out-of-pocket costs after benefits. The class-typical lead-pivotal endpoint here is Weight % change; cells render each drug's actual pivotal endpoint, which may differ. The "Year approved" column shows the FDA approval year for obesity specifically — drugs approved for other indications first appear with their this-indication date, or as Pipeline if not yet approved for this indication. Cross-trial comparisons can mislead — head-to-head Phase-3 data (when present) is below.
Ecnoglutide vs Semaglutide (Wegovy)
No head-to-head Phase-3 trial directly compares Ecnoglutide with Semaglutide.
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Ecnoglutide vs Tirzepatide (Zepbound)
No head-to-head Phase-3 trial directly compares Ecnoglutide with Tirzepatide.
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Ecnoglutide vs Liraglutide (Saxenda, Victoza)
No head-to-head Phase-3 trial directly compares Ecnoglutide with Liraglutide.
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Pipeline alternatives
Investigational agents in active Phase 3 development include Orforglipron from Eli Lilly and Company, an oral GLP-1 receptor agonist, with a lead trial NCT05931380. Also from Eli Lilly and Company, Retatrutide is an investigational GIP, GLP-1, and glucagon receptor agonist, currently undergoing Phase 3 evaluation, including its lead trial NCT05931367. Additionally, Survodutide, developed by Boehringer Ingelheim, is an investigational GLP-1 and glucagon receptor dual agonist, also in active Phase 3 development, with a lead trial NCT06214741.
These investigational agents, while sharing the therapeutic area with Ecnoglutide, present distinct characteristics. Orforglipron offers an oral administration route, differentiating it from Ecnoglutide's injectable format. Retatrutide and Survodutide are multi-agonist compounds, targeting multiple receptors (GIP, GLP-1, glucagon) compared to Ecnoglutide's GLP-1 receptor agonism. In terms of development timeline, these drugs are generally in a similar or slightly earlier stage of Phase 3 development, potentially positioning them approximately 1-2 years behind Ecnoglutide in their clinical journey.
Choosing between Ecnoglutide and its alternatives
Ecnoglutide, a GLP-1 receptor agonist, represents another therapeutic option for weight management. When considering GLP-1 receptor agonists, clinicians typically evaluate agents based on their specific mechanism of action, the magnitude of weight reduction demonstrated in clinical studies, the dosing regimen, and approved indications.
Among currently available options, Tirzepatide (Zepbound), a GIP/GLP-1 dual receptor agonist, demonstrated a mean weight reduction of -22.5% at week 72 with weekly titration dosing. Semaglutide (Wegovy), a GLP-1 receptor agonist, showed a mean weight reduction of -14.9% at week 68 with weekly dosing. For patients where a daily regimen is preferred or for those with specific clinical considerations, Liraglutide (Saxenda), also a GLP-1 receptor agonist, achieved a mean weight reduction of -7.46% at 56 weeks. The choice between these agents may involve weighing these efficacy differences against factors such as dosing frequency and the distinct dual mechanism of Tirzepatide.
Ultimately, the selection of a specific agent is a complex clinical decision, individualized to each patient's needs, comorbidities, and treatment goals, and should be made by the prescribing clinician.
Sources and methodology
Trial data was pulled from the ClinicalTrials.gov registry via the AACT relational mirror maintained by the Clinical Trials Transformation Initiative. AACT data freshness: .
Cross-trial comparison limitations:drugs without a direct head-to-head trial are compared using each drug's own pivotal trial. These trials enrolled different patient populations at different time points and used different statistical analysis sets. Cross-trial response-rate differences should not be interpreted as proof that one drug is more effective than another.
Related drug pages on Hipa.ai
Not medical advice. This page summarizes publicly-reported clinical trial data for informational purposes. Treatment decisions belong with a qualified prescribing clinician who knows your medical history. Drug approvals, dosing, and safety profiles change over time — always confirm with the current FDA prescribing information.
ecnoglutideecnoglutide alternativesalternativescomparisonobesityecnoglutide-glp1-obesityecnoglutide vs semaglutideecnoglutide vs tirzepatideecnoglutide vs liraglutideecnoglutide vs orforglipronecnoglutide vs retatrutide